1-(Cyclopenten-1-yl)-3-(4-methoxyphenyl)propan-1-one | 880476-07-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-(Cyclopenten-1-yl)-3-(4-methoxyphenyl)propan-1-one
• CAS: 880476-07-3
• 化学式: C₁₅H₁₈O₂
• 分子量: 230.307
• InChiKey: XKAOCMSBGIUXPJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(Cyclopenten-1-yl)-3-(4-methoxyphenyl)propan-1-one 在 盐酸 、 sodium tetrahydroborate 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 1-羟基苯并三唑 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 甲醇 为溶剂， 反应 5.0h， 生成
  参考文献：
  名称：

  Synthesis and SAR of 1,2-trans-(1-hydroxy-3-phenylprop-1-yl)cyclopentane carboxamide derivatives, a new class of sodium channel blockers

  摘要：

  Novel cyclopentane-based 3-phenyl-1-hydroxypropyl compounds were evaluated for inhibitory activity against the peripheral nerve sodium channel Na(v)1.7 and off-target activity against the cardiac potassium channel hERG. The stereochemistry of the hydroxyl group and substitution on the phenyl rings with either fluorinated O-alkyl or alkyl groups were found to be critical, for conferring potency against Na(v)1.7. A benchmark compound from this series displayed efficacy in rat models of inflammatory and neuropathic pain. (C) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.11.051
• 作为产物：
  描述：

  环戊烯-1-羧酸甲酯 在 异丙基氯化镁 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 生成 1-(Cyclopenten-1-yl)-3-(4-methoxyphenyl)propan-1-one
  参考文献：
  名称：

  Synthesis and SAR of 1,2-trans-(1-hydroxy-3-phenylprop-1-yl)cyclopentane carboxamide derivatives, a new class of sodium channel blockers

  摘要：

  Novel cyclopentane-based 3-phenyl-1-hydroxypropyl compounds were evaluated for inhibitory activity against the peripheral nerve sodium channel Na(v)1.7 and off-target activity against the cardiac potassium channel hERG. The stereochemistry of the hydroxyl group and substitution on the phenyl rings with either fluorinated O-alkyl or alkyl groups were found to be critical, for conferring potency against Na(v)1.7. A benchmark compound from this series displayed efficacy in rat models of inflammatory and neuropathic pain. (C) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.11.051